4th ICPO FORUM for Theranostics in Precision Oncology, on May 15-16, 2025, in Garching by Munich, Germany

International conference on how to expand patient access to radiotheranostics, an innovative cancer care improving patient outcomes and quality of life.

February 27, 2025 – Wiesbaden, Germany. The ICPO Forum is a unique opportunity to grasp the latest trends on how to expand patient access to theranostics in precision oncology. Forty international experts in this field will present lectures about the global evolution of theranostics, the advances in education and ICPO centers accreditation, radiopharmaceuticals game changers, and the implementation of AI as a backbone for theranostics centers worldwide. Furthermore, the international audience will listen to insights from theranostics experiences from Asia-Pacific, Europe, India, Latin and North America. All participants will be able to exchange with colleagues from the global ICPO Theranostics Community, participate in the industry exhibition, and enjoy the Bavarian evening on May 15, 2025. The Forum will take place at the Science Congress Center Munich (SCCM) in Garching Germany.(www.icpo-forum.org)

Pioneers and renowned experts like Prof. Richard P. Baum, President of ICPO Academy for Theranostics, Germany; Prof.Ken Herrmann, Chair of Nuclear Medicine, at the University Hospital Essen, Germany; Prof. Thomas Beyer, Medical University Vienna, Austria; Prof. Rodney Hicks, Co-founder and CMO, MTIC, Australia and Josh Mailman, Patient Advocate, USA will discuss with high-profile panelists the future of radiotheranostics and its benefits for patients.

Sen. HC Udo J. Vetter, Chairman of the Board of Trustees states: “At the ICPO Foundation, we are fully dedicated to advancing access to theranostics - a game-changer in precision oncology. However, innovation is only meaningful if it reaches those who need it most – the patients. That’s why this forum is more than just a conference - it’s a platform for action for all stakeholders in theranostics.”

Odile Jaume, CEO of the ICPO Foundation, explains: “The 2025 edition reviews international education programs in theranostics, including the ICPO Academy, which offers to train the next generation of healthcare professionals. We will also explore strategies for optimizing theranostics centers, share global experiences, and highlight new radiopharmaceutical advancements for better patient outcomes.“

The ICPO Foundation thanks his esteemed 2025 Forum advisory board for their contributions and exciting lectures: Prof. Richard Baum, President of ICPO Academy for Theranostics, Germany; Prof. Paola Anna Erba, President, EANM, Italy; Prof. Rodney Hicks, Co-founder and CMO, MTIC, Australia; Prof. Thomas Beyer, Medical University Vienna, Austria; Dr. Francesco Giammarile, IAEA, Austria and Mr. Josh Mailman, Patient Advocate, USA

For more info and registration: www.icpo-forum.org

Press registration is free. Please send a mail to: susanne.simon@icpo.foundation

Conference location:
Science Congress Center Munich (SCCM), Walther-von-Dyck-Straße 10, 85748 Garching-Munich, Germany

Program of the 4th ICPO Forum for Theranostics in Precision Oncology

Thursday, May 15, 2025

• Keynote Lectures – Present and Future of Theranostics: Precision medicine benefiting cancer patients (Stephanie Combs); Lancet Oncology Theranostics: Real-world patient benefits (Andrew Scott); Fundamental of ethics in Theranostics: a patient perspective (Josh Mailman); Present & Future of Theranostics applications (Richard P. Baum)
• Growing patient access thanks to professional education in theranostics: Presentations on the role of educational programs and global initiatives like the ICPO Academy for Theranostics (Rod Hicks), IAEA Education Program on Theranostics (Francesco Giammarile) and ESMIT’s RLT Academy. (Paola Anna Erba)
• Enhancing patient access thanks to center initiatives: Accreditation of Theranostics Centers: a global aspiration (Vikas Prasad); Optimization path to a dedicated theranostics center (Desiree Deandreis); New center collaborative developments like Munich Precision Oncology (Matthias Eiber) followed by a panel discussion “The critical path to reach 1 million patients” moderated by Ken Herrmann.
• Global Theranostics Experiences: Insights from North America, (Cathy Cutler) Europe (Pierre-Yves Salaün), Asia-Pacific (Patricia Bautista-Penalosa), India (Partha Choudury), Africa (Masha Maharaj) and Latin America (Maria Agolti), followed by a panel discussion on “What key indicators behind patient experience?” moderated by Josh Mailman
• Networking Opportunities: Visit the industry exhibition and later enjoy the “Bavarian Evening” for informal exchanges.

Friday, May 16, 2025

• New Radiopharmaceuticals, FAP and beyond: FAP clinical establishment and trials update (Frederik Giesel); Trials and advances in FAP and CAIX (David Cade): GPC3 early data in oncology (Wolfgang Weber); Navigating Pitfalls in FAPI PET/CT Interpretation (Akram Al-Ibraheem) followed by a panel discussion “We see it, we treat – are we moving to curative care?” moderated by Rod Hicks.
• Presentation of ICPO Research Grants and Awards: ICPO is happy to feature here a few research projects supported by ICPO grant funding such as AI-powered Global Radiopharmaceutical Trial Finder (Danielle Ralic), Cost-Utility Analysis of RLT in 2nd and 3rd line treatment for mCRPC in Germany (Tom Stargardt), Tolerability of 161Tb-labeled PSMA ligands in immunocompetent mice (Ana Katrina Mapanao) and the prestigious Maurits W. Geerlings Award ceremony.
• TherAInostics or iTheranostics: Discussions on integrating AI into future centers and decision-making processes including Theranostics for Tomorrow (Kevin Ulm); AI based PET image reconstruction, lesion classification and quantitation to assist theranostics decision making (Lance Lingzhi Hu); Perspective from GE Healthcare (Sergio Calvo); ICPO Perspectives and Initiative (Lalith Shiyam Sundar) followed by a survey and panel discussion “AI as a backbone for centers of the future” moderated by Thomas Beyer.
• Future Horizons in targeted alpha therapies: Space for alpha therapy in oncology arsenal (Mike Sathekge); Ac225, path towards secure and sustainable supply (Neil Quigley); At211 thanks to Accelerate.EU initiatives (Hugo Levillain); Pb212 clinical opportunity (Vicki Jardine) followed by a panel discussion “Alpha therapy – game changer in personalized cancer care moderated by Rod Hicks.
• Highlights of the 4th ICPO Forum and Final round table: Highlight by Thomas Beyer then followed by a final round table involving world leading experts present at the ICPO Forum to discuss on “What synergies are needed in the field? What themes are desirable for ICPO Forum 2027? Moderated by Richard P. Baum
• Networking and Exchange

(These highlights are subject to program updates after February 24 2025.)